ATE540971T1 - Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes - Google Patents

Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes

Info

Publication number
ATE540971T1
ATE540971T1 AT06745190T AT06745190T ATE540971T1 AT E540971 T1 ATE540971 T1 AT E540971T1 AT 06745190 T AT06745190 T AT 06745190T AT 06745190 T AT06745190 T AT 06745190T AT E540971 T1 ATE540971 T1 AT E540971T1
Authority
AT
Austria
Prior art keywords
diabetes
type
protein kinase
inhibitors
insulin resistance
Prior art date
Application number
AT06745190T
Other languages
English (en)
Inventor
Eleazar Shafrir
Ehud Ziv
Hadas Reuveni
Masha Niv
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of ATE540971T1 publication Critical patent/ATE540971T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT06745190T 2005-06-29 2006-06-28 Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes ATE540971T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69469105P 2005-06-29 2005-06-29
PCT/IL2006/000755 WO2007000770A2 (en) 2005-06-29 2006-06-28 Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes

Publications (1)

Publication Number Publication Date
ATE540971T1 true ATE540971T1 (de) 2012-01-15

Family

ID=37441619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06745190T ATE540971T1 (de) 2005-06-29 2006-06-28 Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes

Country Status (6)

Country Link
US (1) US8575307B2 (de)
EP (1) EP1896496B1 (de)
JP (1) JP5143729B2 (de)
AT (1) ATE540971T1 (de)
AU (1) AU2006263332B2 (de)
WO (1) WO2007000770A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017444A2 (pt) 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molécula e método
EP3118216A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Zellwachstum und proliferation fördernde peptide und verwendungen davon
KR102307260B1 (ko) 2015-07-16 2021-10-01 뉴리타스 리미티드 항염증 펩티드, 및 그의 용도
EP3117831A1 (de) * 2015-07-16 2017-01-18 Nuritas Limited Peptide zur verwendung bei der förderung des glucosetransports in skelettmuskeln
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
EP3421485A1 (de) * 2017-06-30 2019-01-02 Université de Strasbourg Peptide zur behandlung und prävention von hyperglykämie
RS64265B1 (sr) * 2018-12-21 2023-07-31 Univ Strasbourg Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja
EP4426715A1 (de) * 2021-11-02 2024-09-11 Enumita AS Tri-, tetra- und pentapeptide, zusammensetzungen davon und deren verwendung in der therapie von psoriasis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923802A (en) * 1985-06-13 1990-05-08 Immunex Corporation Peptide substrates for the detection, characterization and purification of protein kinase C
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6723694B1 (en) 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US6717030B2 (en) 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
NZ508767A (en) * 1998-07-06 2003-12-19 Robert O Use of inhibitors of protein kinase c epsilon to treat pain
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
WO2002052033A1 (en) * 2000-12-22 2002-07-04 Joslin Diabetes Center, Inc. Pkc monocyte assay
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6881334B2 (en) * 2002-10-31 2005-04-19 Stanadyne Corporation Eccentric interference retention system for a filter cartridge
CA2539132A1 (en) * 2003-09-16 2005-03-24 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith

Also Published As

Publication number Publication date
EP1896496A2 (de) 2008-03-12
JP2008544980A (ja) 2008-12-11
AU2006263332B2 (en) 2012-02-23
WO2007000770A2 (en) 2007-01-04
US20100216701A1 (en) 2010-08-26
WO2007000770A3 (en) 2007-06-07
EP1896496B1 (de) 2012-01-11
AU2006263332A1 (en) 2007-01-04
JP5143729B2 (ja) 2013-02-13
US8575307B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
WO2008080082A3 (en) Methods for modulating set and uses thereof
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
ATE427116T1 (de) Behandlung von bakteriellen infektionen
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
WO2005002500A3 (en) Inhibitors of coronavirus
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
WO2007000770A3 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
MX392412B (es) Polipéptidos que tienen actividad inductora de inmunidad.
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
WO2005070445A3 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
WO2010012438A3 (en) Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor